ES2487637T3 - Moduladores de PDZ Disheveled - Google Patents

Moduladores de PDZ Disheveled Download PDF

Info

Publication number
ES2487637T3
ES2487637T3 ES11154863.2T ES11154863T ES2487637T3 ES 2487637 T3 ES2487637 T3 ES 2487637T3 ES 11154863 T ES11154863 T ES 11154863T ES 2487637 T3 ES2487637 T3 ES 2487637T3
Authority
ES
Spain
Prior art keywords
disheveled
pdz
terminus
internal region
pdz modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11154863.2T
Other languages
English (en)
Spanish (es)
Inventor
Mike Costa
Sachdev S. Sidhu
Yingnan Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2487637T3 publication Critical patent/ES2487637T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Image Processing (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)
ES11154863.2T 2006-04-10 2007-04-09 Moduladores de PDZ Disheveled Active ES2487637T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79067306P 2006-04-10 2006-04-10
US790673P 2006-04-10

Publications (1)

Publication Number Publication Date
ES2487637T3 true ES2487637T3 (es) 2014-08-22

Family

ID=38537937

Family Applications (2)

Application Number Title Priority Date Filing Date
ES11154863.2T Active ES2487637T3 (es) 2006-04-10 2007-04-09 Moduladores de PDZ Disheveled
ES07760350T Active ES2385261T3 (es) 2006-04-10 2007-04-09 Moduladores de PDZ Disheveled

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES07760350T Active ES2385261T3 (es) 2006-04-10 2007-04-09 Moduladores de PDZ Disheveled

Country Status (8)

Country Link
US (2) US7695928B2 (enExample)
EP (2) EP2343551B1 (enExample)
JP (1) JP5290148B2 (enExample)
CN (2) CN103351425B (enExample)
AU (1) AU2007238186B2 (enExample)
CA (1) CA2648322C (enExample)
ES (2) ES2487637T3 (enExample)
WO (1) WO2007121147A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI494319B (zh) * 2007-02-21 2015-08-01 Oncotherapy Science Inc 表現腫瘤相關抗原之癌症的胜肽疫苗
KR101278073B1 (ko) * 2008-08-04 2013-06-24 연세대학교 산학협력단 Ｉｄｂｆ의 신규 용도
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
BR112014019741A2 (pt) 2012-02-11 2020-12-22 Genentech, Inc Usos de um antagonista da via wnt, uso de uma terapia anticâncer, método de identificação de um indivíduo com câncer, métodos para prever, método de inibição da proliferação de uma célula de câncer, uso de um antagonista da translocação de r-spondina e antagonista da translocação de r-spondina isolado
GB201220901D0 (en) 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived peptides for treating pancreatic cancer
GB201220891D0 (en) 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived peptides for treating breast cancers
TWI658049B (zh) 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗
US9520180B1 (en) 2014-03-11 2016-12-13 Hypres, Inc. System and method for cryogenic hybrid technology computing and memory
GB201421647D0 (en) 2014-12-05 2015-01-21 Amcure Gmbh And Ruprecht-Karls-Universitat And Karlsruher Institut F�R Technologie CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8319174D0 (en) * 1983-07-15 1983-08-17 Erba Farmitalia Biologically active heptapeptides
GB8430255D0 (en) * 1984-11-30 1985-01-09 Erba Farmitalia Biologically active oligopeptides
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
WO1990004788A1 (en) 1988-10-28 1990-05-03 Genentech, Inc. Method for identifying active domains and amino acid residues in polypeptides and hormone variants
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5688936A (en) * 1992-06-11 1997-11-18 The Regents Of The University Of California Vesicle membrane transport proteins
JPH08503950A (ja) 1992-12-02 1996-04-30 アルカーメス・コントロールド・セラピユーテイクス・インコーポレーテツド 徐放性成長ホルモン含有マイクロスフェア
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
EP1002529A1 (en) 1994-09-09 2000-05-24 Takeda Chemical Industries, Ltd. Sustained-release preparation containing a metal salt of a peptide
SK281571B6 (sk) 1995-06-07 2001-05-10 Alkermes Controlled Therapeutics, Inc. Prostriedok na trvalé uvoľňovanie ľudského rastového hormónu
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
US6294330B1 (en) 1997-01-31 2001-09-25 Odyssey Pharmaceuticals Inc. Protein fragment complementation assays for the detection of biological or drug interactions
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
WO2000006717A2 (en) 1998-07-27 2000-02-10 Genentech, Inc. Improved transformation efficiency in phage display through modification of a coat protein
US6610836B1 (en) * 1999-01-29 2003-08-26 Genome Therapeutics Corporation Nucleic acid amino acid sequences relating to Klebsiella pneumoniae for diagnostics and therapeutics
WO2002090544A2 (en) 2001-05-04 2002-11-14 Hybrigenics Protein-protein interactions in adipocyte cells (3)
WO2003004604A2 (en) * 2001-07-06 2003-01-16 Genentech, Inc. Phage displayed pdz domain ligands
US7314974B2 (en) * 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
EP1549144A4 (en) 2002-10-04 2010-01-06 Univ California METHOD FOR THE TREATMENT OF CANCER BY INHIBITION OF THE WNT SIGNALING LINE
JP2008505183A (ja) * 2004-07-01 2008-02-21 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア Ｐｄｚ−ドメイン相互作用阻害小分子

Also Published As

Publication number Publication date
WO2007121147A3 (en) 2008-01-10
CN101467039A (zh) 2009-06-24
CA2648322A1 (en) 2007-10-25
EP2343551A1 (en) 2011-07-13
US20080167386A1 (en) 2008-07-10
CN103351425A (zh) 2013-10-16
EP2343551B1 (en) 2014-05-28
CN101467039B (zh) 2013-11-06
WO2007121147A2 (en) 2007-10-25
ES2385261T3 (es) 2012-07-20
EP2002259B1 (en) 2012-05-16
EP2002259A2 (en) 2008-12-17
AU2007238186A1 (en) 2007-10-25
US7977064B2 (en) 2011-07-12
JP2009533465A (ja) 2009-09-17
JP5290148B2 (ja) 2013-09-18
HK1131438A1 (en) 2010-01-22
US7695928B2 (en) 2010-04-13
CA2648322C (en) 2017-11-28
CN103351425B (zh) 2016-01-20
US20100136580A1 (en) 2010-06-03
AU2007238186B2 (en) 2014-01-09

Similar Documents

Publication Publication Date Title
ES2486675T3 (es) Análogo de péptido de oxintomodulina
ES2523837T3 (es) Agentes de unión específica al factor de crecimiento de hepatocitos
ES2512141T3 (es) Análogo peptídico de oxintomodulina
ES2535084T3 (es) Proteínas N-glicosiladas recombinantes procedentes de células procariotas
ES2525477T3 (es) Anticuerpos anti-factor D humanizados
ES2629749T3 (es) Inmunidad tumoral
ES2528346T3 (es) Derivado de péptido insulinotrópico en el que se ha modificado su aminoácido N-terminal
ES2596880T3 (es) Composición para el análisis de glicoproteínas
ES2616658T3 (es) Péptidos que mimetizan el factor de crecimiento y sus usos
ES2665917T3 (es) Endoxifeno para su uso en el tratamiento del cáncer
CO5720212A1 (es) Composicion de anticuerpo her2
ES2513392T3 (es) Materiales biológicos y usos de los mismos
ES2548238T3 (es) Formulaciones antagonistas de VEGF
ES2502472T3 (es) Composición adhesiva para su uso en un inmunosensor
CL2012002522A1 (es) Composición farmacéutica que comprende un compuesto inhibidor de dpp iv con un grupo amino o una sal del mismo , un primer diluyente , un segundo diluyente ,un aglutinante , un disgregante y un lubricante, útil en el tratamiento de diabetes mellitus.
CR9975A (es) Anticuerpos antagonistas dirigidos contra el péptido relacionado con el gen de calcitonina
CR9452A (es) Agentes terapeuticos a base de peptidos de toxinas
ES2534744T3 (es) Plasmina modificada de forma recombinante
UY28641A1 (es) Anticuerpos
ES2572388T3 (es) Heterodímeros del MHC de clase II solubles funcionales estabilizados por enlaces disulfuro
AR065370A1 (es) Moduladores de htra1 - pdz y htra3 pdz
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
ES2525758T3 (es) Composición que comprende un péptido y un inhibidor de la neuraminidasa vírica
EA200700973A1 (ru) Слитый белок, содержащий домен bh3 белка «вh3-только»
ES2616017T3 (es) Composiciones que contienen sulfato de condroitina, nattocinasa y compuestos de sulfhidrilo para su uso en el tratamiento de inflamación